GSK in Agreement to Acquire Aiolos

Cleary Gottlieb is representing GSK in its entrance into an agreement on January 8, 2024, to acquire Aiolos Bio Inc. (Aiolos) for a $1 billion upfront payment and up to $400 million in certain success-based regulatory milestone payments.

The acquisition provides GSK with access to Aiolos’ AIO-001, a potentially best-in-class, long-acting anti-thymic stromal lymphopoietin (TSLP) monoclonal antibody ready to enter Phase II clinical development for the treatment of adult patients with asthma, with potential for additional indications including chronic rhinosinusitis with nasal polyps. AIO-001 was exclusively licensed to Aiolos outside of Greater China by Jiangsu Hengrui Pharmaceuticals Co. Ltd.

GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together.

Founded in 2023, Aiolos is a San Francisco- and London, UK-based clinical-stage, private, biopharmaceutical company dedicated to revolutionizing the treatment landscape for respiratory disease. The company is focused on addressing the unmet treatment needs of patients with certain respiratory and inflammatory conditions.

For more information, please see the press release here.